Brokerage firm BMO Capital Downgrades its rating on Mead Johnson Nutrition CO(MJN). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by the stock financial advisor at BMO Capital was issued on Feb 13, 2017 in a research report to their Investors and Clients.
In a different note, On Feb 2, 2017, Berenberg said it Upgrades its rating on Mead Johnson Nutrition CO. The shares have been rated ‘Hold’ by the firm. Berenberg said it Initiates Coverage On Mead Johnson Nutrition CO, according to a research note issued on Jan 18, 2017. In the research note, the firm Announces the price-target to $66 per share. The shares have been rated ‘Sell’ by the firm.
Mead Johnson Nutrition CO (MJN) made into the market gainers list on Wednesdays trading session with the shares advancing 0.03% or 0.03 points. Due to strong positive momentum, the stock ended at $87.5, which is also near the day’s high of $87.63. The stock began the session at $87.42 and the volume stood at 47,05,557 shares. The 52-week high of the shares is $94.4 and the 52 week low is $69.25. The company has a current market capitalization of $16,046 M and it has 18,33,84,500 shares in outstanding.
Mead Johnson Nutrition CO(MJN) last announced its earnings results on Jan 26, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $901.600M. Analysts had an estimated revenue of $925.330M. Earnings per share were $0.78. Analysts had estimated an EPS of $0.82.
Several Insider Transactions has been reported to the SEC. On Nov 1, 2016, Anna C Catalano (director) sold 656 shares at $74.99 per share price.Also, On Aug 15, 2016, Kimberly A Casiano (director) sold 710 shares at $89.75 per share price.On Aug 5, 2016, Graciela Monteagudo (SVP&PresAmericas&Glob.Market’g) sold 45,873 shares at $87.69 per share price, according to the Form-4 filing with the securities and exchange commission.
Mead Johnson Nutrition Company (Mead Johnson) is a global pediatric nutrition company. The Company manufactures distributes and sells infant formulas children’s nutrition and other nutritional products. Its product portfolio includes routine and specialty infant formulas childrens milks and milk modifiers dietary supplements for pregnant and breastfeeding mothers pediatric vitamins and products for pediatric metabolic disorders. The Company operates through three segments: Asia Latin America and North America/Europe. The Company’s Enfa family of brands including Enfamil infant formula is a brand franchise in pediatric nutrition. Its product portfolio addresses a range of nutritional needs for infants children and expectant and nursing mothers. The Company markets its portfolio of more than 70 products to mothers healthcare professionals and retailers in more than 50 countries in Asia North America Latin America and Europe.